Aytu Biopharma (AYTU) Accounts Payables (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Accounts Payables data on file, last reported at $13.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $13.2 million, up 9.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (up 9.74% YoY), and the FY2025 annual result was $10.6 million, up 2.78% from the prior year.
• Accounts Payables slipped to $13.2 million in Q1 2026 per AYTU's latest filing, from $14.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.7 million in Q1 2023 and troughed at $10.3 million in Q2 2024.
• A 5-year average of $12.3 million and a median of $12.0 million in 2025 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 56.31% in 2022 and fell as far as 42.94% in 2022.
• A 5-year view of Accounts Payables shows it stood at $10.6 million in 2022, then fell by 1.01% to $10.5 million in 2023, then advanced by 11.71% to $11.7 million in 2024, then grew by 21.88% to $14.3 million in 2025, then declined by 7.33% to $13.2 million in 2026.
• Business Quant data shows AYTU's Accounts Payables at $13.2 million in Q1 2026, $14.3 million in Q4 2025, and $12.3 million in Q3 2025.